Skip to main content
Equibles
INM logo

INM · InMed Pharmaceuticals Inc. · Metrics

Track INM — free

Use INM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.33 -0.02 (-1.48%) At close · Oct 2
Rebalance outlook locked
Going-concern doubt — flagged Sep 9, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.”
View the 10-K filed Sep 9, 2026
Market Cap
$7.58M
Shares
5.49M
Volume · Oct 2 28.34K Avg daily vol (3M) 916.81K

INM metrics

58 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.33
Market cap
$7.58M

Price action

20 metrics
Price change (1W)
-3.6%
Price change (30D)
-3.6%
Price change (3M)
-14.7%
Price change (6M)
+96.2%
Price change (YTD)
+25.5%
Price change (1Y)
-41.2%
Trailing year
Price change (5Y)
—
52-week high
$2.46
52-week low
$0.62
Change from 52-week high
-45.9%
Change from 52-week low
+116.3%
Annualized volatility
154.2%
Annualized volatility (3M)
59.0%
Beta
0.4
RSI (14D)
43.3
Price vs SMA 50
-6.4%
Price vs SMA 200
+12.6%
Avg volume (3M)
916,805
Relative volume
0.0
Average dollar volume
$1.51M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
5.49M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.7×
reciprocal yield 59.4%
P / book
7.1
reciprocal yield 14.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-165.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2021-06-30

Profitability

9 metrics
Gross margin
29.7%
Operating margin
—
Trailing 12 months
Net margin
-165.1%
Gross profit (TTM)
$1.34M
Operating profit (TTM)
−$6.97M
Net income (TTM)
−$12.56M
Trailing 12 months
Diluted EPS (TTM)
$-3.12
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.20

Growth

11 metrics
Revenue growth YoY
-26.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$4.51M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+269.4%
Year over year · more shares
Revenue CAGR (3Y)
+65.5%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-1,168.4%
Return on assets
-414.5%
Debt / equity
—
Current ratio
1.4
EBITDA (TTM)
−$6.77M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$2.19M
Total assets
$3.03M
Total debt
$29,312

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$8.64M
Capital expenditures (TTM)
—
R&D (TTM)
$3.03M
SG&A (TTM)
—
Stock compensation (TTM)
$106,866
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
20
13F filer change QoQ
+11
Institutional ownership
49.1%

Short interest

3 metrics
Short interest
0.3%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
33 / 100

Insider activity

2 metrics
Net insider buying (90D)
$151,477
Insider-sentiment score
90 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1728328 CUSIP 457637700 Visit website Investor relations